ライフサイエンスコーパス: opioid analgesic

1 uropathic pain states that are refractive to opioid analgesics.

2 s had symptomatic, metastatic HRPC requiring opioid analgesics.

3 oagulants, antibiotics, diabetes agents, and opioid analgesics.

4 ide-effect profiles over currently available opioid analgesics.

5 iation of metastatic bony pain compared with opioid analgesics.

6 therapies as safe and potentially abuse-free opioid analgesics.

7 phine or other conventional bimodally-acting opioid analgesics.

8 nal Cav2.3 channels as potential targets for opioid analgesics.

9 a strong therapeutic advantage over standard opioid analgesics.

10 f a new class of drugs known collectively as opioid analgesics.

11 making progress in controlling the abuse of opioid analgesics.

12 ate to severe pain that needs treatment with opioid analgesics.

13 mitigate the need for standard postoperative opioid analgesics.

14 strategy for the production of longer acting opioid analgesics.

15 r (MOR) is the principle molecular target of opioid analgesics.

16 r (MOR) is the principle molecular target of opioid analgesics.

17 and diversion of pharmaceuticals, primarily opioid analgesics.

18 tor target for both endogenous and exogenous opioid analgesics.

19 ates the hypnotic response to high levels of opioid analgesics.

20 , motivating efforts toward developing novel opioid analgesics.

21 for standard treatments such as radiation or opioid analgesics.

22 The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investi

23 As prescription opioid analgesic abuse rates rise, so does the need to u

24 e to increases in the health consequences of opioid analgesic abuse.

25 brain cytochrome P450 (P450) activity in mu opioid analgesic action, we generated a mutant mouse wit

26 These findings indicate altered endogenous opioid analgesic activity in FM and suggest a possible r

27 The amount of opioid analgesic administered by the nurse correlated mo

28 to the suspension of therapy and a need for opioid analgesic and enteral/parenteral nutrition, with

29 reated due in part to reluctance about using opioid analgesics and fear that they will be abused.

30 data on misuse and diversion of prescription opioid analgesics and heroin.

31 ain entails the use of nonopioid analgesics, opioid analgesics, and adjuvants singly or in combinatio

32 nal status, the need for corticosteroids and opioid analgesics, and survival time.

33 Opioid analgesics are commonly used in chronic pain mana

34 national expert groups have determined that opioid analgesics are essential for the relief of pain,

35 dal analgesic regimens continues to improve; opioid analgesics are increasingly taking on the role of

36 Opioid analgesics are the standard therapeutic agents fo

37 Opioid analgesics are traditionally the treatment for th

38 Although opioid analgesics are typically embraced as the mainstay

39 Opioid analgesics are used extensively in the management

40 lead compound in the search for nonaddictive opioid analgesic as its signaling profile suggests that

41 nist-stimulated [(35)S]GTPgammaS binding and opioid analgesic assays; however, gene knockout of JNK 1

42 Prescription of opioid analgesics at discharge.

43 This article describes the major opioid analgesics available for the treatment of cancer-

44 The responses to the delta opioid analgesic [d-Pen(2),d-Pen(5)]enkephalin were unaf

45 response in HRPC patients with significant, opioid analgesic-dependent pain.

46 ci previously shown to associate with higher opioid analgesic dose were associated with higher methad

47 ntribute to the acute and chronic actions of opioid analgesic drugs.

48 sociated with an enhanced sensitivity to the opioid analgesic effect (IL-1beta, P = 0.0218; TNF-alpha

49 G9a inhibitors may be used to enhance the opioid analgesic effect in the treatment of chronic neur

50 role of G9a in diminished MOR expression and opioid analgesic effects in animal models of neuropathic

51 receptors (CBRs) have been implicated in the opioid analgesic effects.

52 lopment of therapies to maximize and sustain opioid analgesic efficacy.

53 ificant drug-drug interaction that modulates opioid analgesic efficacy.

54 The ultra-potent opioid analgesic, etorphine, elicits naloxone-reversible

55 asticity that are differentially affected by opioid analgesic exposure and are likely important media

56 parenteral and transdermal delivery forms of opioid analgesics; external beam irradiation; and system

57 Opioid analgesic fills in the year before transplantatio

58 The prescribing of opioid analgesics for pain management-particularly for m

59 orting outcomes of RCT/s comparing 2 or more opioid analgesics for the management of chronic pain wer

60 low effectiveness of morphine and related mu opioid analgesics for the treatment of chronic inflammat

61 However, 59.6% disagreed with the use of opioid analgesics for treatment of those patients.

62 t is involved in brain-to-blood transport of opioid analgesics (i.e., morphine).

63 -)-conolidine are potent and efficacious non-opioid analgesics in an in vivo model of tonic and persi

64 ared the doses and duration of sedatives and opioid analgesics in patients receiving low vs. traditio

65 However, consumption of opioid analgesics in the region is low and data suggest

66 umber of drug abuse mentions per year due to opioid analgesics increased from 32,430 to 34,563 (6.6%)

67 Prescriptions for opioid analgesics increased substantially from 2002 thro

68 ical trial was designed to evaluate pain and opioid analgesic intake as surrogates for antitumor resp

69 Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC

70 In addition to pain and opioid analgesic intake, prostate-specific antigen (PSA)

71 Unintentional overdose involving opioid analgesics is a leading cause of injury-related d

72 Abuse of prescription opioid analgesics is a serious threat to public health,

73 While the therapeutic effect of opioids analgesics is mainly attributed to micro-opioid

74 Improgan, a non-opioid analgesic, is known to act in the rodent brain st

75 The choice of the opioid analgesic, its route of administration, dose, and

76 The data suggest that spinal opioid analgesic mechanisms, acting alone or in synergy

77 46.8 [range, 0 to 110]; P<0.001), the use of opioid analgesics (median, 212 mg of morphine equivalent

78 iallodynic effects that last longer than the opioid analgesic morphine.

79 ents showed that acute administration of the opioid analgesic, morphine (5.6 mg/kg; IP), attenuated P

80 ic efficacy of two other predominantly kappa-opioid analgesics, nalbuphine and butorphanol; was compa

81 lly related alkaloids have been described as opioid analgesics, no therapeutically relevant propertie

82 ntation of these patients and the effects of opioid analgesics on mu-opioid receptors.

83 Opioid analgesics, once considered the standard approach

84 2.0; 95% CI, 1.2 to 3.2), and treatment with opioid analgesics (OR, 1.6; 95% CI, 1.0 to 2.5).

85 CLINICAL QUESTION Do the benefits of opioid analgesics outweigh the risks in patients with pe

86 A single in vivo exposure to the opioid analgesic oxycodone disrupted mu OP-LTD and endoc

87 roducts and formulations of six prescription opioid analgesics: oxycodone, hydrocodone, hydromorphone

88 Prescription opioid analgesics play an important role in the treatmen

89 Adherence rates for opioid analgesics prescribed on an around-the-clock (ATC

90 Overall adherence rates for ATC opioid analgesics ranged from 84.5% to 90.8% and, for PR

91 Opioid analgesics remain the choice for the treatment of

92 -2 positively modulates the actions of other opioid analgesics, such as fentanyl and methadone.

93 eltaR antinociception.SIGNIFICANCE STATEMENT Opioid analgesics, such as morphine, which target the mu

94 r the discovery and development of novel non-opioid analgesics, such as subtype-selective sodium chan

95 ain higher and be more willing to administer opioid analgesics than were physicians.

96 The generation of potent opioid analgesics that lack the side effects of traditio

97 reased abuse potential compared with current opioid analgesics that target the mu opioid receptor.

98 ts the randomization criteria (i.e. need for opioid analgesics) the patient will be randomized to eit

99 isease (SCD), for which patients may require opioid analgesics throughout life.

100 somewhere between the two extremes in using opioid analgesics to cope with their psychological or sp

101 imal therapeutic profile, the search for non-opioid analgesics to replace these well-established ther

102 ntensity and were more willing to administer opioid analgesics to them than to their demographic coun

103 The trend of increasing medical use of opioid analgesics to treat pain does not appear to contr

104 lead to further evaluate the role of P-gp in opioid analgesic tolerance development.

105 (P = .01) was observed between reductions in opioid analgesic use and pain scores only for those pati

106 tile range, 4 to 34), and 38% of the men had opioid analgesic use at baseline.

107 perative ileus (POI) is often exacerbated by opioid analgesic use during and following surgery, since

108 so in secondary analyses, mean cumulative IV opioid analgesic use was reduced by 83% with GMI-1070 vs

109 status, disease site, lactate dehydrogenase, opioid analgesic use, albumin, hemoglobin, prostate-spec

110 Opioid analgesic use, average mouth and throat soreness

111 s in the diversion and abuse of prescription opioid analgesics using data through 2013.

112 The need for corticosteroids and opioid analgesics was significantly reduced in the surgi

113 vious study of rheumatology clinic patients, opioid analgesics were found to be highly effective, pro

114 Opioid analgesics were taken by 275 decedents (93.2%), o

115 lasses (anticoagulants, diabetes agents, and opioid analgesics) were implicated in an estimated 59.9%

116 -clinical profile of a highly effective, non-opioid analgesic when administered into the rodent CNS.

117 n the chemical synthesis of desmethylprodine opioid analgesic, which induces Parkinson disease.

118 ve pain management due to adverse effects of opioid analgesics, which can impede recovery; a problem

119 Despite the skilled use of opioid analgesics, which is crucial to the relief of can

120 Thus, [Dmt(1)]DALDA is a highly selective mu-opioid analgesic with significant pharmacological differ

121 These results show that dipyrone, a non-opioid analgesic with widespread use in Europe and Latin

122 peutic targets, as illustrated by our unique opioid analgesics with a vastly improved pharmacological

123 Opioid analgesics with both micro and delta opioid recep

124 gstanding interest in the development of new opioid analgesics with improved therapeutic profiles.

125 ents a promising lead for the development of opioid analgesics with reduced side effects.

126 thus a promising lead for the development of opioid analgesics with reduced tolerance.

127 we observed increased intrinsic efficacy of opioid analgesics with two antinociceptive tests: hot wa

128 no previous research has substantiated safe opioid analgesics without abuse liability in primates.